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Abstract
In chronic obstructive pulmonary disease (COPD/emphysema) we have shown a reduced ability of lung and alveolar (AM)
macrophages to phagocytose apoptotic cells (defective ‘efferocytosis’), associated with evidence of secondary cellular
necrosis and a resultant inflammatory response in the airway. It is unknown whether this defect is present in cancer (no
COPD) and if so, whether this results from soluble mediators produced by cancer cells. We investigated efferocytosis in AM
(26 controls, 15 healthy smokers, 37 COPD, 20 COPD+ non small cell lung cancer (NSCLC) and 8 patients with NSCLC without
COPD) and tumor and tumor-free lung tissue macrophages (21 NSCLC with/13 without COPD). To investigate the effects of
soluble mediators produced by lung cancer cells we then treated AM or U937 macrophages with cancer cell line
supernatant and assessed their efferocytosis ability. We qualitatively identified Arachidonic Acid (AA) metabolites in cancer
cells by LC-ESI-MSMS, and assessed the effects of COX inhibition (using indomethacin) on efferocytosis. Decreased
efferocytosis was noted in all cancer/COPD groups in all compartments. Conditioned media from cancer cell cultures
decreased the efferocytosis ability of both AM and U937 macrophages with the most pronounced effects occurring with
supernatant from SCLC (an aggressive lung cancer type). AA metabolites identified in cancer cells included PGE2. The
inhibitory effect of PGE2 on efferocytosis, and the involvement of the COX-2 pathway were shown. Efferocytosis is
decreased in COPD/emphysema and lung cancer; the latter at least partially a result of inhibition by soluble mediators
produced by cancer cells that include PGE2.
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Introduction
COPD is predicted to become the third most prevalent cause of
death worldwide by 2020 [1]. The carcinogenic effects of tobacco
smoke have been well-described; however, smokers with COPD
have a higher risk of developing lung cancer than do smokers
without COPD [2] even when corrected for tobacco consumption.
The prevalence of COPD and lung cancer is projected to increase
in the coming decades due to continued exposure to risk factors
and an ageing population. These statistics are alarming as lung
cancer is responsible for more cancer-related deaths than colon,
breast and prostate cancers combined [3]. Although smoking
cessation remains paramount, many new lung cancers are detected
in ex- rather than current smokers. There is an urgent need to
better understand the links between smoking, COPD and lung
cancer to enable novel therapeutic or preventative strategies.
We have shown that alveolar macrophages (AM) in COPD are
defective in their capacity to phagocytose apoptotic cells (effer-
ocytosis) [4–7], which has the potential to contribute to the excess
apoptotic material that we have reported in the COPD airway [8].
This un-cleared material can then undergo secondary necrosis and
perpetuate the inflammatory response [8]. At this stage it is
unknown whether there is also a defect in the efferocytosis ability
of lung tissue macrophages from COPD subjects, although our
findings with a smoking mouse model suggest that this may be the
case [9,10]. Also unknown is whether there are defects in the
efferocytosis ability of AM and lung tissue/tumor-associated
macrophages from patients with cancer in the absence of COPD,
and if so, whether soluble mediators produced by the lung cancer
cells inhibit efferocytosis.
Evidence suggests that un-cleared apoptotic material that results
from defective efferocytosis, in addition to its inflammatory effects,
can stimulate the influx of regulatory T lymphocytes which exert
immuno-suppressive effects against anti-tumor immunity and thus
contribute to the tumor’s ability to escape eradication [11].
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Whether defects in the mechanisms that lead to defective
efferocytosis in COPD also play a direct role in creating a pro-
tumour environment and contribute to an increased susceptibility
to lung cancer is unknown.
Cancer cells are directly immunosuppressive by releasing pro-
inflammatory mediators including Arachidonic Acid (AA) metab-
olites such as prostaglandins (PGE) [12]. PGE is released in cells
expressing constitutive cyclooxygenase-2 (COX-2), regulated by
liberation of AA by phospholipase A 2 followed by metabolism by
COX. PGE2 has been shown to decrease phagocytosis of bacteria
via an E-prostanoid 2 receptor -mediated process [13].
We therefore investigated efferocytosis in AM from controls,
smokers, current/ex-smoker COPD subjects and patients with non
small cell lung cancer (NSCLC) with/without COPD. We also
investigated macrophages from tumor and tumor-free tissues
obtained at lobectomy from patients with NSCLC with/without
COPD.
We then investigated whether soluble mediators produced by
lung cancer cells would directly suppress macrophage efferocytic
ability. We assessed the effect of supernatant from cancer cell
cultures on efferocytosis then applied electrospray ionization
tandem mass spectrometry (LC-ESI-MSMS) analysis for AA
metabolites in lung cancer cells. We finally investigated the
potential for the COX inhibitor indomethacin to improve
efferocytosis.
Materials and Methods
Subject population and bronchoalveolar lavage samples
(BAL)
Cancer and COPD groups included patients undergoing
bronchoscopy at the Royal Adelaide Hospital (RAH) to investigate
suspected lung cancer. We included a small group of patients with
lung cancer without COPD to further dissect the effects of lung
cancer alone versus COPD. Controls, smokers and some COPD
subjects were recruited from our volunteer database. Controls had
normal lung function and no history of lung disease, cancer or
allergy. We have previously found no significant differences in
efferocytosis between never-smoker and ex-smoker controls and
therefore grouped them together as ‘control group’. Written
informed consent was obtained with ethics approval granted by
the RAH.
Flexible bronchoscopy was performed and bronchoalveolar
lavage samples (BAL) obtained according to recommendations by
the American Thoracic Society as previously reported [4–7,14].
For patients with cancer, the BAL was taken well away from the
affected region of the lung. Spirometric assessment of predicted
values and lower limits of normality (LLN) for forced vital capacity
(FVC), forced expiratory volume in first second (FEV(1)), and
FEV(1)/FVC ratio was performed and the diagnosis of COPD
established using the Global Initiative for Chronic Obstructive
Lung Disease (GOLD) criteria (FEV1/FVC ,70%) with x-ray
and clinical correlation [15]. For three patients where FEV1/FVC
was slightly higher that LLN, the presence of emphysema was
confirmed with high resolution CT or x-ray; these patients were
therefore included. Cancer patients all had NSCLC diagnosed on
the basis of World Health Organization criteria [16] and were
further categorized on the presence of COPD. Microbiological
colonization and differential cell counts were assessed by SA
Pathology (Adelaide, South Australia).
We investigated efferocytosis in AM from 24 controls, 15
healthy smokers, 20 current/16 ex-smoker COPD subjects and 8
patients with NSCLC without COPD and 17 with COPD
(Table 1). We also investigated macrophages from tumor and
tumor-free tissues obtained at lobectomy from patients with
NSCLC (21 with/13 without COPD) (Table 2).
Lung tissues samples
Tumor and non-tumor lung tissue were obtained from patients
undergoing lobectomy at the Department of Cardiothoracic
Surgery, RAH, following informed consent, as previously
described [17,18]. Tumor was obtained using a biopsy needle,
while biopsies were collected from non-tumor (‘normal’) areas well
away from the cancer (approximately 5 mm65 mm in size).
Biopsies were performed by a qualified surgical pathologist,
ensuring that representative tumor and normal tissue samples were
collected. A ‘Medimachine’ tissue disaggregator (BD) was applied
to prepare single cell suspensions from lung tissue as previously
described [9,17].
Samples were categorized as ‘Control (non-tumor)’ (non-cancer
area from patients with cancer/no COPD), ‘Control (tumor)’
(cancer site from patients with cancer/no COPD), ‘COPD (non-
tumor)’ (non-cancer area from patients with cancer+COPD) and
‘COPD (tumor)’ (cancer site from patients with cancer+COPD).
Preparation of macrophages
Macrophages from BAL and tissue were isolated as reported [4–
7] (detailed in Supporting Information S1).




















Controls 57 [44–75] 7[3] 101.6 [2.9] 79.5 [1.9] 103.2 [4.0] 79.5 [2.0] 68.1 [0.6] 0/8/16 10/14 67.7 [3.8] 0.21 [.04] 77.4 [4.0] 11.6
[1.6]
Healthy smokers 50 [29–66] 34[7] 92.3 [2.6] 74.8 [1.4] 99.6 [2.6] 77.7 [2.2] 69.4 [0.9] 13/0/0 9/6 66.3 [4.6] 1.13 [.55]* 85.8 [3.2] 9.5 [2.5]
COPD Cur-smoker 60 [37–75] 49[7]* 71.8 [3.0]* 60.0 [2.0]* 77.6 [3.3] 60.9 [2.0] 67.2 [0.6] 20/0/0 11/9 49.9 [3.5]* 0.36 [.10] 81.6 [4.2] 6.6 [1.8]
COPD ex-smoker 64 [55–73]* 58[15]* 71.9 [4.1]* 58.4 [3.3]* 76.8 [5.0] 58.3 [2.4] 66.6 [1.0] 0/16/0 10/6 51.3 [6.3] 0.35 [.05] 74.4 [8.9] 8.6 [1.7]
COPD +cancer 67 [55–77]* 35[7] 66.5 [2.0]* 62.3 [2.3]* 69.2 [2.3] 63.3 [2.5] 65.3 [0.4] 11/9/0 14/6 55.4 [5.2] 0.20 [.07] 86.3 [3.5] 5.9 [1.2]
Cancer no COPD 61 [44–75] 11[7] 91.8 [5.3] 78.6 [0.9] 94.1 [6.7] 89.7 [6.9] 66.8 [1.0] 4/1/3 4/4 49.2 [9.8]* 0.34 [.07] 73.2 [11.4] 6.6 [1.4]
doi:10.1371/journal.pone.0061573.t001
Lung Macrophage Phagocytosis in COPD and Cancer
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Immunological reagents and cell lines
Immunological reagents, cell lines (normal human bronchial
epithelial cells (16HBE), lung adenocarcinoma (H2009, H1466),
and small-cell carcinoma (SBC-1)) and culture/stimulation condi-
tions are detailed in Supporting Information S1.
Efferocytosis ability of BAL, tissue and U937
macrophages
Efferocytosis was investigated by flow cytometry as reported [4–
























































































































































































































































































































































































































































































































Figure 1. Efferocytosis ability of alveolar and lung tissue
macrophages. A. Efferocytosis of BAL-derived alveolar macrophages
was assessed for controls (‘C’), smokers, current- and ex- smokers with
COPD (‘COPD Cur’ and ‘COPD Ex’), COPD subjects with lung cancer
(‘COPD Cancer’) and patients with lung cancer and no COPD (‘Cancer’);
B. Tissue from Controls (‘C Non-Tumor’) (non-cancer area from patients
with cancer/no COPD), ‘COPD Non-Tumor’ (non-cancer area from
patients with cancer+COPD), ‘COPD Tumor’ (cancer site from patients
with cancer+COPD) and ‘Control Tumor’ (cancer site from patients with
cancer/no COPD). *significantly (p,0.05) lower expression vs. controls
(non-parametric Kruskal-Wallis test)Box plots present median625th and
75th percentiles (solid box) with the 10th and 90th percentiles shown
by whiskers outside the box.
doi:10.1371/journal.pone.0061573.g001
Lung Macrophage Phagocytosis in COPD and Cancer
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LC-ESI-MSMS analysis for AA metabolites in cultured lung
cancer cells
20 mL 46105 cancer cells or primary airway epithelial cells
obtained by bronchial brushings at bronchoscopy (as control) were
assessed for the presence of AA and COX derived AA metabolites
(PGE2, PGD2, PGF2a, TXN2, 6ketoPGF1, 11-hydroxyeicosate-
traenoic acid (11-HETE), thromboxane B2 (TxB2); lipoxygenase
(LOX) products (12- and 5- HETE); eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA), (8-HODE, LTB4), 12(5)TETE,
PGB2 and 13(5)HODE using LC-ESI-MSMS as detailed in
Supporting Information S1.
Effect of prostaglandins on efferocytosis
Preparation of conditioned media from cancer cell lines is
described in Supporting Information S1. We firstly investigated
the effects of endogenous PGE2 on efferocytosis. U937 macro-
phages were treated with varying concentrations of PGE2 (0.1–
10 mM) prior to assessment of efferocytosis. Having shown a dose-
dependent effect on efferocytosis we then assessed the potential
effects of PGE2 produced by lung cancer cells on efferocytosis.
Cells were treated with supernatant from SBC-1 cells6the COX
inhibitor indomethacin (1–10 mM) before assessing the effects of
cancer cell supernatant on efferocytosis.
Statistical analysis
Kruskal-Wallis and Spearman’s rank correlation tests were
applied. For in vitro experiments, ‘treatment’ results were
compared with controls [RPMI media treatment] using one-way
ANOVA and Dunnett’s test.
Results
Patient demographics
BAL volumes were significantly reduced for current-smoker
COPD and cancer (no COPD) groups vs. controls (Table 1). Total
WCC was increased in current-smokers without COPD vs.
controls (Table 1). Typical BAL yielded 75– 95% AM. There
were no significant differences in% AM or lymphocytes in any
patient group vs. controls (Table 1) although there was a non-
significant trend for a reduced% of lymphocytes in the cancer
groups.
BAL and tissue macrophage efferocytosis
Significantly decreased efferocytosis was noted in cancer and
COPD groups for both AM and lung tissue macrophages, and for
AM from healthy smokers. Efferocytosis varied between compart-
ments, with AM showing a greater phagocytic ability than tissue or
tumour macrophages, regardless of COPD status (COPD:
(mean6SEM) BAL 12.8360.87 .non-tumour tissue
8.67%60.52 .7.48%60.78; Non-COPD: BAL 20.3061.79
.non-tumour tissue 9.45%60.48 .7.80%60.68). In COPD,
efferocytosis was decreased independently of smoking status and
lung cancer (Figure 1). For tissue macrophages, efferocytosis was
decreased in COPD to the same extent in tissue adjacent to
tumour and in unaffected areas, while in cancer patients without
COPD, efferocytosis was decreased only in tumour areas. There
were no significant differences in efferocytosis between BAL
macrophages from COPD vs. COPD patients with cancer
(Figure 1) or between COPD non-cancer vs. COPD cancer tissue
macrophages
Figure 2. Effect of cancer cell line supernatants on efferocytosis. A. Effect of cancer cell line supernatants on the phagocytosis of apoptotic
bronchial epithelial cells by alveolar macrophages. Macrophages from (A) control subjects or (B) subjects with lung cancer were incubated in normal
RPMI media or cancer cell line supernatants (H2009, H1466, SBC1) for 24 hrs prior to phagocytosis assay. Values are presented as percentage of
macrophages ingesting apoptotic cells *, p, 0.05 compared with RPMI media treatment (n = 5 experiments performed in triplicate; one-way ANOVA,
Dunnett’s test). Data presented as box plots as described in Figure 1.
doi:10.1371/journal.pone.0061573.g002
Figure 3. Effect of prostaglandins on efferocytosis. Prostaglan-
dins inhibit efferocytosis and at least partially mediate the inhibitory
effect of cancer cell line supernatants on the phagocytosis of apoptotic
bronchial epithelial cells by U937 cells. U937 cells were incubated with
varying concentrations of PGE2 for 18 hours and efferocytosis assessed
(n = 3 triplicate experiments; one-way ANOVA, Dunnett’s test).
doi:10.1371/journal.pone.0061573.g003
Lung Macrophage Phagocytosis in COPD and Cancer
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Lung cancer cell line supernatant inhibit efferocytosis
AM from controls or subjects with lung cancer were co-cultured
with supernatant from NSCLC (H2009, H1466), and SCLC
(SBC-1) cells. For AM from controls, lung cancer supernatant
significantly decreased efferocytosis by 29%–33% (Figure 2).
Interestingly, supernatant did not affect the (already significantly
reduced) efferocytosis ability of AM from lung cancer subjects.
Lung cancer cell lines contain AA metabolites
All three lung cancer cell lines (A549, H2009, SBC-1) showed
detectable levels of PGE2, PGD2, PGF2a, TXN2 and 6ketoPGF1.
11-HETE, TxB2; 12- and 5- HETE; EPA, DHA), 8-HODE,
LTB4, 12(5)TETE, PGB2 and 13(5)HODE were not identified.
Based on the presence of PGE2 we then investigated the effects of
the COX inhibitor, indomethacin, on efferocytosis.
PGE-2 inhibits efferocytosis
Exposure of U937 cells to PGE2 dose-dependently reduced
their efferocytosis ability in a dose-dependent manner, with
maximum and significant inhibition occurring in the presence of
10 mM PGE2 (Figure 3). To investigate the potential effects of
PGE2 produced by lung cancer cells (via the COX-2/PGE-2
pathway) on efferocytosis, we then treated SBC1 cells with the
COX inhibitor indomethacin. SBC1 cells were selected for these
experiments as they had the greatest effect on efferocytosis.
Indomethacin had no negative effects on cell growth or viability of
the SBC-1 cells at the concentrations used (data not shown). We
determined the effect of SBC-1 cell supernatant on PMA-
differentiated U937 macrophages. Supernatant from SBC-1 cells
grown in the absence of indomethacin significantly decreased the
efferocytosis ability of U937 cells by 36% (Figure 4). This decrease
was partially inhibited by indomethacin (1 mM: 21.3% increase vs.
cancer cell supernatant; 10 mM: 25.74% increase).
Discussion
A better understanding of the links between COPD and lung
cancer is critical to advise novel therapeutic or preventative
strategies. We report that the efferocytosis ability of both alveolar
and lung tissue macrophages is deficient in patients with lung
cancer with or without COPD (in COPD, independently of
smoking status and lung cancer). In COPD, efferocytosis was
decreased to a similar extent in tissue macrophages adjacent to the
tumour and in unaffected areas, while in cancer patients without
COPD, the defect was noted only in the tumour-associated
macrophages, implying that COPD and cancer both result in
impaired efferocytosis, by partly independent mechanisms. Un-
cleared apoptotic material is likely to be important in the
progression of lung cancer as this material has been shown to
have pro-inflammatory effects [19] and contribute to a tumor’s
ability to escape eradication by several mechanisms including
stimulating of an influx of regulatory T lymphocytes [12]. Patients
treated with rituximab, a drug which acts in part by opsonizing
cells and increasing phagocytosis had a positive prognostic value
despite the high number of tumor-associated macrophages
[20,21].
Phagocytosis may be suppressed via release of soluble mediators
including PGE-2 by lung cancer cells. In mesothelioma; cancer
cells co-cultured with macrophages induced a decrease in
phagocytosis but an increase in the PGE-2 release [22]. In the
present study we therefore applied LC-ESI-MSMS to determine
whether lung cancer cells produced various prostaglandins that
could directly inhibit efferocytosis. All three lung cancer cell lines
produced detectable levels of AA metabolites including PGE-2,
consistent with another study [23] of NSCLC cell lines A549 and
H1299. Inhibition of COX with indomethacin at least partially
negated the suppressive effects on efferocytosis, implicating an
effect of the COX-2/PGE-2 pathway although there are clearly
other additional factors involved.
Interestingly, the most significant suppressive effects were found
using the SCLC cell line, SBC-1 and we can hypothesize that this
may be representative of the more aggressive nature of this lung
cancer type. A previous study of COX-2 expression in primary
NSCLC demonstrated the highest levels of both mRNA and
protein in adenocarcinoma cells compared with large cell and
squamous cell carcinoma [24]. They did not, however, investigate
SCLC. It will be of interest to determine whether AA metabolites
inhibit the efferocytosis function of airway and tumor-associated
macrophages to a similar extent, as we found that lung cancer cell
supernatant had a significant suppressive effect on the efferocytic
ability of macrophages from control subjects but did not affect the
(already significantly reduced) efferocytic ability of macrophages
from subjects with lung cancer.
Drawbacks of the study are that we were not able to compare
BAL and lung tissue compartments for individual patients; we are
however assessing this in our murine emphysema model in
ongoing studies. There are also obvious ethical drawbacks of
obtaining fresh ‘normal’ lung. Although we collected our ‘control’
lung tissue by biopsy taken well away from the area of cancer in
patients without COPD, the possibility still remains that the
presence of cancer may have influenced some of our findings and
murine cancer models are required to clarify this. The number of
NSCLC patients without COPD was relatively low (BAL from 8
patients with NSCLC and paired cancer and cancer-free tissue
from 13 patients was obtained over a 2 year period) which
precludes firm conclusions based on analysis of data from this
group of patients. Of the about 200 patients with NSCLC, which
our unit sees annually only a small percentage (,15%) are
considered for surgery (Stages I and II), and of those many are
medically inoperable. In our operable patients with NSCLC the
proportion of patients without COPD is very low, about 10%.
In conclusion we have shown decreased efferocytosis in airway
and lung tissue in both COPD and lung cancer, and the inhibition
of efferocytosis via release of soluble prostaglandins by lung cancer
Figure 4. Prostaglandin inhibition of efferocytosis involves
COX-2. U937 cells were incubated in normal RPMI media or SBC-1
supernatant that had been treated with indomethacin. Following 24 hrs
incubation, an efferocytosis assay was performed. (n = 5 experiments
performed in triplicate). Data presented as box plots as described in
Figure 1. Values are presented as percentage of macrophages ingesting
apoptotic cells *, p,0.05 compared with RPMI media treatment (one-
way ANOVA, Dunnett’s test).
doi:10.1371/journal.pone.0061573.g004
Lung Macrophage Phagocytosis in COPD and Cancer
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cells. These defects may be a potential immune evasion
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